Issued 2026-08-13 at $178.94 · now $166.28 (2026-08-13, −7.1% since)
Based on its own history, a month from the 2026-08-13 close, BLTE has typically landed between $139.27 and $256.42 — a range of −22.2% to +43.3% from the issuance price $178.94.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,055 overlapping 1 month windows · 2022-04-29 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($178.94) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where BLTE has typically landed a month from the 2026-08-13 close of $178.94 — the range is history, not a prediction.
- now $166.28 (-7.1%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $185.1 (+3.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $165.41–$204.78
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $139.27–$256.42
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2023-05-23 | −52.8% | −52.8% | +0.9% |
| 2023-05-22 | −48.9% | −48.9% | +0.0% |
| 2023-05-05 | −46.5% | −46.5% | +0.0% |
| 3 best | |||
| 2022-06-02 | +196.3% | +0.0% | +196.3% |
| 2022-06-07 | +180.9% | +0.0% | +187.6% |
| 2022-06-03 | +175.0% | +0.0% | +194.3% |
1,055 overlapping windows · 2022-04-29 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2027-06-30 — Trial primary completion: Phase 3 primary completion: Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy (source, as of 2026-08-14)
- February 2028 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.